|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 90 No. 8 (October 15), 1997:
pp. 3167-3172
A High Pretreatment Serum Vascular Endothelial Growth Factor Concentration Is Associated With Poor Outcome in Non-Hodgkin's Lymphoma
By
Petri Salven,
Lasse Teerenhovi, and
Heikki Joensuu
From the Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, FIN-00290 Helsinki, Finland.
 |
ABSTRACT |
Vascular endothelial growth factor (VEGF ) is a secreted endothelial cell-specific mitogen, which is induced by hypoxia and is angiogenic in vivo. Recently, elevated serum concentrations of VEGF (S-VEGF ) have been reported in patients with cancers of various histologies. However, the prognostic significance of S-VEGF in human cancer is unknown and the origin of S-VEGF remains unsettled. We measured S-VEGF by enzyme-linked immunosorbent assay from sera taken from 82 patients with non-Hodgkin's lymphoma before treatment and stored for 9 to 15 years at -20°C. All but one of the patients had been followed-up for at least 5 years or until death. S-VEGF ranged from 15 to 964 pg/mL; median, 228 pg/mL; mean, 291 pg/mL. A higher than the median S-VEGF level was associated with a poor World Health Organization performance status, a high International Prognostic Index, a high serum lactate dehydrogenase level, and a large cell histology. Patients with lower than the median S-VEGF at diagnosis had a 71% 5-year survival rate in comparison with only 49% among those with a higher than the median S-VEGF. We conclude that a high pretreatment S-VEGF level is associated with poor outcome in non-Hodgkin's lymphoma.
| |
INTRODUCTION |
ANGIOGENESIS, the sprouting of new capillaries from preexisting ones, is an important component in many physiological and pathological processes. In healthy adults extensive angiogenesis occurs only in the female reproductive system. Angiogenesis may also take place in some pathological conditions, such as wound healing, rheumatoid arthritis, diabetic retinopathy, and tumor growth (reviewed by Folkman1 ).
During tumorigenesis, the vasculature can become activated to grow new capillaries in response to an appropriate stimulus (reviewed by Hanahan and Folkman2 ). One such stimulus is vascular endothelial growth factor (VEGF ), also called vascular permeability factor (VPF ), which is a soluble, dimeric 46-kD protein that is active as an endothelial cell-specific mitogen and as a vascular permeability factor (reviewed by Ferrara3 and Dvorak et al4 ). As a result of alternative splicing of VEGF mRNA, there exist at least three isoforms of VEGF encompassing 121, 165, and 189 amino acid residues.5 The two shorter forms are efficiently secreted from cells, whereas the longer one remains mostly cell associated. VEGF is induced by hypoxia in vitro and in vivo.6-10 Tumor cells have been shown to express both VEGF mRNA and protein in a variety of human cancers,11-14 and it has been concluded that VEGF has an important role in tumor biology and in the process of tumor angiogenesis (reviewed by Dvorak et al4 ). Expression of VEGF has been detected also in lymphoma.15 Furthermore, VEGF protein purified from a human histiocytic lymphoma cell line promoted dermal blood vessel leakage in guinea pigs at a dose of 20 ng and promoted in vitro endothelial cell growth at concentrations as low as 50 pmol/L.16 Expression of VEGF has been shown to increase tumor growth and angiogenesis in vivo in a nude mouse model.17-19 Similarly, anti-VEGF antibodies have the ability to inhibit the growth of several tumor cell lines in nude mice.20-22
Recently, elevated serum VEGF concentrations (S-VEGF ) have been observed in patients with various histological types of cancer.23,24 High S-VEGF has also been associated with a large size of the primary breast tumor and a short tumor volume doubling time in advanced colorectal cancer.23,25 However, little is known about the clinical significance of S-VEGF, and there are no studies available on the prognostic value of S-VEGF in any type of human cancer. In the present study we measured S-VEGF from lymphoma patients' sera stored for years at -20°C and found that S-VEGF values were associated with survival and several important clinical variables.
| |
MATERIALS AND METHODS |
Patients
S-VEGF was measured in 82 randomly selected adult patients with non-Hodgkin's lymphoma diagnosed and treated in the Department of Oncology, Helsinki University Central Hospital in 1981 to 1987, of whom frozen serum taken at the time of diagnosis but before possible lymphoma treatment was available. Histological classification was not reviewed in conjunction with the present study, but 18 lymphomas (22%) had been classified as low-grade, 40 (49%) intermediate-grade, and 22 (27%) as high-grade lymphoma according to the Working Formulation scheme26 by a pathologist with a special interest in lymphoma, and 2 (2%) cases were considered unclassifiable.
Thirty-eight (46%) of the patients were men, and the median age at diagnosis was 60 years. Clinical staging was done according to the Ann Arbor classification system. The clinical status, a chest radiograph, computed tomography (CT) scans of the mediastinum and abdomen, and a bone marrow biopsy were taken as staging examinations. Twenty-two (27%) of the patients had stage I, 24 (29%) stage II, 14 (17%) stage III, and 22 (27%) stage IV disease at diagnosis. Fifteen patients (18%) had B symptoms (weight loss, unexplained fever, or night sweats). The International Prognostic Index (IPI)27 could be determined in 79 (96%) cases.
A total of 68 patients were treated with combination chemotherapy. The patients with intermediate- or high-grade lymphoma and disseminated disease were treated usually with bleo-CHOP (bleomycin, cyclophosphamide, doxorubicin, vincristine, and prednisone), M-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone), or another anthracycline containing a combination chemotherapy regimen. Low-grade lymphomas were usually treated with a single agent chlorambucil if symptomatic. Twenty-eight patients received megavoltage radiotherapy.
All patients were regularly followed-up with a few months intervals in an outpatient department. The median follow-up time was 84 months (range, 33 to 136 months), and all but one patient were followed up over 60 months or until death. During the follow-up time 38 patients died.
Methods
Venous blood samples.
Peripheral venous blood samples were collected in sterile test tubes a few hours or a few days before starting lymphoma therapy, centrifuged at 2,000g for 10 minutes, and then stored at -20°C.
View this table:
[in this window]
[in a new window]
|
Table 2.
Association Between the Pretreatment S-VEGF Level and Nine Clinicopathological Factors in Non-Hodgkin's Lymphoma
|
|
S-VEGF immunoassay.
S-VEGF concentrations were determined as S-VEGF immunoreactivity by using a quantitative sandwich enzyme immunoassay technique (Quantikine R; R & D Systems, Minneapolis, MN). The system uses a solid phase monoclonal antibody and an enzyme-linked polyclonal antibody raised against recombinant human VEGF. For each analysis 100 µL of serum was used. All analyses and calibrations were performed in duplicate. The calibrations on each microtiter plate included recombinant human VEGF standards. Optical densities were determined by using a microtiter palate reader (Multiscan RC Type 351; Labsystems, Helsinki, Finland) at 450 nm. The blank was subtracted from the duplicate readings for each standard and sample. A standard curve was created using StatView 4.02 (Abacus Concepts Inc, Berkeley, CA) by plotting the logarithm of the mean absorbance of each standard versus the logarithm of the VEGF concentration. Concentrations are reported as pg/mL. The coefficient of variation of interassay determinations reported by the manufacturer vary from 6.2% to 8.8% when the S-VEGF concentrations range between 50 and 1,000 pg/mL. When we measured 12 serum samples twice in two separate assays, the interassay variation ranged from 2% to 9% within the same concentration range. The possible effect of freezing on S-VEGF was investigated by measuring S-VEGF before and after a freeze-thawing cycle in serum samples taken from six cancer patients and from six healthy volunteers. S-VEGF levels were determined without any knowledge of the survival or other clinical data except age and sex of the patients, which could be found on the test tube labels.
Statistical analysis.
Statistical analysis was done by using the BMDP software (BMDP Statistical Software Inc, Los Angeles, CA). Cumulative survival was estimated with the product-limit method from the date of diagnosis. The Mantel-Cox log-rank test and the generalized Wilcoxon test were used to compare survival between different groups. The relative importance of different variables was analyzed using Cox's proportional hazard model (BMDP 2L). Frequency tables were analyzed with the  2 test or Fisher's exact test. The effect of freezing on S-VEGF was analyzed with the Wilcoxon signed rank test. All P values are two tailed.
| |
RESULTS |
The Effect of Freezing on VEGF Concentrations of Serum Samples
The effect of freeze thawing was studied in 12 serum samples. Before freezing, S-VEGF of the 12 samples tested ranged from 23 to 2,703 pg/mL; median, 261 pg/mL; mean, 670 pg/mL, and after freezing and thawing, the range was from 22 to 3,114 pg/mL; median, 263 pg/mL; mean, 719 pg/mL (P > .1; Table 1). Hence, freezing and thawing of the serum samples did not have any marked effect on S-VEGF values.
View this table:
[in this window]
[in a new window]
|
Table 3.
Association Between Pretreatment S-VEGF and the Histological Type of Non-Hodgkin's Lymphoma by the Working Formulation Scheme
|
|
View larger version (22K):
[in this window]
[in a new window]
| Fig 1.
Survival of 82 patients with non-Hodgkin's lymphoma by the pretreatment S-VEGF level. The median (228 pg/mL) was used as the cut-off value. Survival rates at 24, 60, and 96 months are given.
|
|
Serum VEGF in Non-Hodgkin's Lymphoma
Serum VEGF concentrations ranged from 15 to 964 pg/mL (median, 228 pg/mL; mean 291 pg/mL) among the 82 patients with non-Hodgkin's lymphoma. One third of the patients had S-VEGF lower than 122 pg/mL and one third higher than 314 pg/mL.
If the median S-VEGF concentration was used as the cut-off value, a high S-VEGF was strongly associated with a poor World Health Organization (WHO) performance status (>1, P = .002), a higher than the normal serum lactate dehydrogenase (S-LDH) level measured at the time of the diagnosis (P = .005), a high IPI (>2, P = .003), and a possible association was found with the female gender (P = .08; Table 2). No association between a high pretreatment S-VEGF and age at diagnosis, Ann Arbor stage, or the presence of B-symptoms was found (P > .10). Similarly, no association between S-VEGF and the Working Formulation grading was found (P = .82), but patients with large cell lymphoma (either large cell diffuse, G, n = 27; immunoblastic, H, n = 14; lymphoblastic, I, n = 2; or histiocytic lymphoma, n = 1) had more often a higher than the median pretreatment S-VEGF level in comparison with the rest of the patients (P = .03; Table 3).
S-VEGF and Survival
Patients with higher than the median S-VEGF had inferior survival in comparison with those with lower than the median pretreatment value (P = .04 by the log-rank test and .01 by the generalized Wilcoxon test; Fig 1). The 2- and 5-year survival rates of the patients with a lower than the median S-VEGF level were 85% and 71%, respectively, and those of the patients with a higher than the median level, 59% and 49%, respectively. A high S-VEGF level was associated with inferior survival also when tertiles and quartiles were used as cut-off values (Table 4). A higher than the median S-VEGF was associated with poor overall survival among patients with low-grade lymphoma (5-year survival 56% v 100%; P = .04) and those with high-grade lymphoma (5-year survival 25% v 50%; P = .03), but in intermediate-grade lymphomas the difference was not statistically significant (62% v 67%; P > .1). When survival in the subgoup of large cell diffuse and immunoblastic lymphomas (n = 41) was analyzed separately, patients with a higher than the median S-VEGF (269 pg/mL) had inferior survival in comparison with patients with lower than the median S-VEGF, but the difference was not statistically significant (2-year survival 55% v 71%; 5-year survival 44% v 52%; P > .1).
Several other factors correlated strongly with overall survival in univariate survival analyses in the present series (Table 4). Therefore, S-VEGF using the median as the cut-off value was tested in a multivariate analysis together with the IPI score, gender, and the presence of B symptoms using Cox's proportionate hazard model. In this analysis, only the IPI score had independent influence on survival (P < .001, the relative risk of death 2.3, 95% confidence interval from 1.7 to 3.2).
| |
DISCUSSION |
In the present study we found many patients with non-Hodgkin's lymphoma to have an elevated pretreatment S-VEGF concentration. The pretreatment S-VEGF of non-Hodgkin's lymphoma patients ranged from 15 to 964 pg/mL (median, 228 pg/mL; mean, 291 pg/mL). In comparison, the S-VEGF in 184 healthy individuals reported by Yamamoto et al23 varied from values that were under the detection limit to 228 pg/mL. The results of Yamato et al are in line with our experience, because we have only rarely measured VEGF concentrations higher than 150 pg/mL in sera of presumably healthy individuals (range from 1 to 177 pg/mL; n = 113).24
We found a high pretreatment S-VEGF to be associated with poor overall survival and a few established adverse prognostic factors in non-Hodgkin's lymphoma. S-VEGF did not have independent prognostic value when the IPI was included in a multivariate analysis, but it should be noted that in a univariate analysis S-VEGF was about as strong a prognostic factor as age at diagnosis, which is currently included as a component together with stage, S-LDH level, the number of extranodal sites, and the WHO performance status in the IPI.27 Although first designed for aggressive non-Hodgkin's lymphomas, the IPI has been shown to be useful in all grades of lymphoma.28 However, the present findings should be interpreted with some caution because the series is heterogeneous and includes several types of non-Hodgkin's lymphoma.
In lymphoma and several other types of human cancer the cancer cells produce VEGF.4,15 Hypoxia has been considered to be an important stimulus for VEGF production in tumor cells, but also various cytokines such as interleukin-6, epidermal growth factor, transforming growth factor- 1, keratinocyte growth factor, and tumor necrosis factor- have been shown to induce the expression of VEGF in cultured cells.29,30 Lymphocytes infiltrating human cancers, macrophages, and peripheral blood T lymphocytes and platelets also contain VEGF.31-34 Therefore, circulating VEGF found in patients with cancer may originate from cancer cells but also from tumor infiltrating benign cells and circulating peripheral blood cells. However, it should be noted that not all of the proteins stored in blood cells are endogenously synthesized, but instead may originate primarily from plasma.35,36 Consequently, it is possible that VEGF secreted by cancer cells or by tumor infiltrating inflammatory cells escapes to the circulation and accumulates in the blood cells, such as platelets and lymphocytes.
In the present study we measured higher than the median S-VEGF values more frequently from large cell lymphomas than from small cell or mixed cell lymphomas, and high S-VEGF levels were also associated with a poor WHO performance status, a high serum LDH level, and the IPI. These findings are not in contradiction with the hypothesis that high serum VEGF levels are associated with growth of lymphoma and active angiogenesis. The biological role of circulating VEGF in cancer progression and dissemination may be of importance. VEGF in the tumor microenvironment not only stimulates proliferation of tumor blood vessels, but also increases vascular permeability (reviewed by Dvorak et al4 ), thus, possibly contributing to tumor cell extravasation and metastasis formation. Moreover, VEGF has recently been found to inhibit maturation of dendritic cells, which are important antigen-presenting cells.37 Hence, exposure of the immune system to high levels of local and possibly also circulating VEGF may play a role in allowing tumors to avoid induction of an immune response.
In conclusion, these data indicate that a high S-VEGF level is associated with poor outcome in non-Hodgkin's lymphoma. A high pretreatment S-VEGF may be associated with active tumor angiogenesis and tumor growth, and it is possible that similar associations with unfavorable survival can be found in other types of human cancer as well. Further studies are now needed in non-Hodgkin's lymphoma to find out whether S-VEGF is a prognostic factor in single histological types of the disease and whether S-VEGF values are associated with the proliferation rate of lymphoma. It will be of particular interest to find out whether S-VEGF levels predict response to antiangiogenic drugs in lymphoma and in other types of human malignancy. In addition, further studies are required to investigate the origin of circulating VEGF as well as its levels in conditions such as infectious and inflammatory states.
| |
FOOTNOTES |
Submitted December 31, 1996;
accepted June 13, 1997.
Supported by grants from the Finnish Academy, the Finnish Cancer Foundation, and the Helsinki University Central Hospital Research Funds.
Address reprint requests to Heikki Joensuu, MD, PhD, Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, FIN-00290 Helsinki, Finland.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
We thank Elina Roimaa for technical assistance.
| |
REFERENCES |
1.
Folkman J:
Angiogenesis in cancer, vascular, rheumatoid and other disease.
Nature Med
1:27,
1995[Medline]
[Order article via Infotrieve]
2.
Hanahan D,
Folkman J:
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell
86:353,
1996[Medline]
[Order article via Infotrieve]
3.
Ferrara N:
The role of vascular endothelial growth factor in pathological angiogenesis.
Breast Cancer Res Treat
36:127,
1995[Medline]
[Order article via Infotrieve]
4.
Dvorak HF,
Brown LF,
Detmar M,
Dvorak AM:
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.
Am J Pathol
146:1029,
1995[Abstract]
5.
Tischer E,
Mitchell R,
Hartman T,
Silva M,
Gospodarowicz D,
Fiddes JC,
Abraham JA:
The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.
J Biol Chem
266:11947,
1991[Abstract/Free Full Text]
6.
Shweiki D,
Itin A,
Soffer D,
Keshet E:
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.
Nature
359:843,
1992[Medline]
[Order article via Infotrieve]
7.
Shweiki D,
Neeman M,
Itin A,
Keshet E:
Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis.
Proc Natl Acad Sci USA
92:768,
1995[Abstract/Free Full Text]
8.
Namiki A,
Brogi E,
Kearney M,
Kim EA,
Wu T,
Couffinhal T,
Varticovski L,
Isner JM:
Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells.
J Biol Chem
270:31189,
1995[Abstract/Free Full Text]
9.
Banai S,
Shweiki D,
Pinson A,
Chandra M,
Lazarovici G,
Keshet E:
Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: Implications for coronary angiogenesis.
Cardiovasc Res
28:1176,
1994[Abstract/Free Full Text]
10.
Pe'er J,
Shweiki D,
Itin A,
Hemo I,
Gnessin H,
Keshet E:
Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases.
Lab Invest
72:638,
1995[Medline]
[Order article via Infotrieve]
11.
Brown LF,
Berse B,
Jackman RW,
Tognazzi K,
Manseau EJ,
Dvorak HF,
Senger DR:
Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas.
Am J Pathol
143:1255,
1993[Abstract]
12.
Brown LF,
Berse B,
Jackman RW,
Tognazzi K,
Manseau EJ,
Senger DR,
Dvorak HF:
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.
Cancer Res
53:4727,
1993[Abstract/Free Full Text]
13.
Plate KH,
Breier G,
Weich HA,
Mennel HD,
Risau W:
Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms.
Int J Cancer
59:520,
1994[Medline]
[Order article via Infotrieve]
14.
Weninger W,
Uthman A,
Pammer J,
Pichler A,
Ballaun C,
Lang I,
Plettenberg A,
Bankl HC,
Stürzl M,
Tschachler E:
Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors.
Lab Invest
75:647,
1996[Medline]
[Order article via Infotrieve]
15.
Dvorak HF,
Sioussat TM,
Brown LF,
Berse B,
Nagy JA,
Sotrel A,
Manseau EJ,
Van de Water L,
Senger DR:
Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels.
J Exp Med
174:1275,
1991[Abstract/Free Full Text]
16.
Connolly DT,
Heuvelman DM,
Nelson R,
Olander JV,
Eppley BL,
Delfino JJ,
Siegel NR,
Leimgruber RM,
Feder J:
Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.
J Clin Invest
84:1470,
1989
17.
Ferrara N,
Winer J,
Burton T,
Rowland A,
Siegel M,
Phillips HS,
Terrell T,
Keller GA,
Levinson AD:
Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells.
J Clin Invest
91:160,
1993
18.
Zhang HT,
Craft P,
Scott PA,
Ziche M,
Weich HA,
Harris AL,
Bicknell R:
Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells.
J Natl Cancer Inst
87:213,
1995[Abstract/Free Full Text]
19.
Claffey KP,
Brown LF,
Aguila L,
Tognazzi K,
Yeo KT,
Manseau EJ,
Dvorak HF:
Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis.
Cancer Res
56:172,
1996[Abstract/Free Full Text]
20.
Kim KJ,
Li B,
Winer J,
Armanini M,
Gillett N,
Phillips HS,
Ferrara N:
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.
Nature
362:841,
1993[Medline]
[Order article via Infotrieve]
21.
Asano M,
Yukita A,
Matsumoto T,
Kondo S,
Suzuki H:
Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
Cancer Res
55:5296,
1995[Abstract/Free Full Text]
22.
Warren RS,
Yuan H,
Matli MR,
Gillett NA,
Ferrara N:
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
J Clin Invest
95:1789,
1995
23.
Yamamoto Y,
Toi M,
Kondo S,
Matsumoto T,
Suzuki H,
Kitamura M,
Tsuruta K,
Taniguchi T,
Okamoto A,
Mori T,
Yoshida M,
Ikeda T,
Tominaga T:
Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients.
Clin Cancer Res
2:821,
1996[Abstract]
24.
Salven P,
Mäenpää H,
Orpana A,
Alitalo K,
Joensuu H:
Serum VEGF is often elevated in disseminated cancer.
Clin Cancer Res
6:647,
1997
25.
Dirix LY,
Vermeulen PB,
Hubens G,
Benoy I,
Martin M,
De Pooter C,
Van Oosterom AT:
Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer.
Ann Oncol
7:843,
1996[Abstract/Free Full Text]
26.
National Cancer Institute sponsored study on classification of non-Hodgkin's lymphomas:
Summary and description of a working formulation for clinical usage.
Cancer
49:2112,
1982[Medline]
[Order article via Infotrieve]
27. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 14:987, 1993
28.
Hermans J,
Krol AD,
van Groningen K,
Kluin PM,
Kluin-Nelemans JC,
Kramer MH,
Noordijk EM,
Ong F,
Wijermans-PW:
International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades.
Blood
86:1460,
1995[Abstract/Free Full Text]
29.
Cohen T,
Nahari D,
Cerem LW,
Neufeld G,
Levi BZ:
Interleukin 6 induces the expression of vascular endothelial growth factor.
J Biol Chem
271:736,
1996[Abstract/Free Full Text]
30.
Frank S,
Hubner G,
Breier G,
Longaker MT,
Greenhalgh DG,
Werner S:
Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing.
J Biol Chem
270:12607,
1995[Abstract/Free Full Text]
31. Salven P, Heikkilä P, Joensuu H: Enhanced expression of VEGF in metastatic melanoma. Br J Cancer (in press)
32.
Freeman MR,
Schneck FX,
Gagnon ML,
Corless C,
Soker S,
Niknejad K,
Peoples GE,
Klagsbrun M:
Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis.
Cancer Res
55:4140,
1995[Abstract/Free Full Text]
33.
Berse B,
Brown LF,
van de Water L,
Dvorak HF,
Senger DR:
Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.
Mol Biol Cell
3:211,
1992[Abstract]
34.
Möhle R,
Green D,
Moore MAS,
Nachman RL,
Rafii S:
Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets.
Proc Natl Acad Sci USA
94:663,
1997[Abstract/Free Full Text]
35.
Harrison P,
Wilbourn B,
Debili N,
Vainchenker W,
Breton Gorius J,
Lawrie AS,
Masse JM,
Savidge GF,
Cramer EM:
Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets.
J Clin Invest
84:1320,
1989
36.
Harrison P,
Cramer EM:
Platelet alpha-granules.
Blood Rev
7:52,
1993[Medline]
[Order article via Infotrieve]
37.
Gabrilovich DI,
Chen HL,
Girgis KR,
Cunnigham HT,
Meny GM,
Nadaf S,
Kavanaugh D,
Carbone DP:
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dentritic cells.
Nature Med
2:1096,
1996[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H D Hosgood III, L Zhang, M Shen, S I Berndt, R Vermeulen, G Li, S Yin, M Yeager, J Yuenger, N Rothman, et al.
Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity
Occup. Environ. Med.,
December 1, 2009;
66(12):
848 - 853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Robertson, B. S. Kahl, J. M. Vose, S. de Vos, M. Laughlin, P. J. Flynn, K. Rowland, J. C. Cruz, S. L. Goldberg, L. Musib, et al.
Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
May 1, 2007;
25(13):
1741 - 1746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Gratzinger, S. Zhao, R. J. Marinelli, A. V. Kapp, R. J. Tibshirani, A. S. Hammer, S. Hamilton-Dutoit, and Y. Natkunam
Microvessel Density and Expression of Vascular Endothelial Growth Factor and Its Receptors in Diffuse Large B-Cell Lymphoma Subtypes
Am. J. Pathol.,
April 1, 2007;
170(4):
1362 - 1369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos and D. Morgensztern
Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
February 20, 2006;
24(6):
995 - 1007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Keller, A. V. Schally, K. Groot, G. L. Toller, A. Havt, F. Koster, P. Armatis, G. Halmos, M. Zarandi, J. L. Varga, et al.
Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone
PNAS,
July 26, 2005;
102(30):
10628 - 10633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Younes, B. Pro, M. J. Robertson, I. W. Flinn, J. E. Romaguera, F. Hagemeister, N. H. Dang, P. Fiumara, E. M. Loyer, F. F. Cabanillas, et al.
Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin's Lymphoma and Hodgkin's Disease
Clin. Cancer Res.,
August 15, 2004;
10(16):
5432 - 5438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bono, A. Krause, M. von Mehren, M. C. Heinrich, C. D. Blanke, S. Dimitrijevic, G. D. Demetri, and H. Joensuu
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib
Blood,
April 15, 2004;
103(8):
2929 - 2935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T.-P. Poon, C. P.-Y. Lau, S.-T. Cheung, W.-C. Yu, and S.-T. Fan
Quantitative Correlation of Serum Levels and Tumor Expression of Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma
Cancer Res.,
June 15, 2003;
63(12):
3121 - 3126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. F. Dvorak
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy
J. Clin. Oncol.,
November 1, 2002;
20(21):
4368 - 4380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hayashibara, Y. Yamada, T. Miyanishi, H. Mori, T. Joh, T. Maeda, N. Mori, T. Maita, S. Kamihira, and M. Tomonaga
Vascular Endothelial Growth Factor and Cellular Chemotaxis: A Possible Autocrine Pathway in Adult T-Cell Leukemia Cell Invasion
Clin. Cancer Res.,
September 1, 2001;
7(9):
2719 - 2726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Wong, M. Alfert, D. H. Castrillon, Q. Shen, J. Holash, G. D. Yancopoulos, and L. Chin
Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome
PNAS,
June 7, 2001;
(2001)
121192298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Niemelä, H. Mäenpää, P. Salven, P. Summanen, K. Poussa, L. Laatikainen, J. Jääskeläinen, and H. Joensuu
Interferon {{alpha}}-2a Therapy in 18 Hemangioblastomas
Clin. Cancer Res.,
March 1, 2001;
7(3):
510 - 516.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. T.-P. Poon, S.-T. Fan, and J. Wong
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
J. Clin. Oncol.,
February 15, 2001;
19(4):
1207 - 1225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold
Increased Serum Concentration of Angiogenic Factors in Malignant Melanoma Patients Correlates With Tumor Progression and Survival
J. Clin. Oncol.,
January 15, 2001;
19(2):
577 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Braybrooke, K. J. O’Byrne, D. J. Propper, A. Blann, M. Saunders, N. Dobbs, C. Han, J. Woodhull, K. Mitchell, J. Crew, et al.
A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis
Clin. Cancer Res.,
December 1, 2000;
6(12):
4697 - 4704.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Salven, A. Orpana, L. Teerenhovi, and H. Joensuu
Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients
Blood,
December 1, 2000;
96(12):
3712 - 3718.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Aguayo, H. Kantarjian, T. Manshouri, C. Gidel, E. Estey, D. Thomas, C. Koller, Z. Estrov, S. O'Brien, M. Keating, et al.
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
Blood,
September 15, 2000;
96(6):
2240 - 2245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Aguayo, S. O'Brien, M. Keating, T. Manshouri, C. Gidel, B. Barlogie, M. Beran, C. Koller, H. Kantarjian, and M. Albitar
Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia
Blood,
July 15, 2000;
96(2):
768 - 770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Bertolini, L. Fusetti, P. Mancuso, A. Gobbi, C. Corsini, P. F. Ferrucci, G. Martinelli, and G. Pruneri
Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma
Blood,
July 1, 2000;
96(1):
282 - 287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Federico, U. Vitolo, P. L. Zinzani, T. Chisesi, V. Clo, G. Bellesi, M. Magagnoli, M. Liberati, C. Boccomini, P. Niscola, et al.
Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases
Blood,
February 1, 2000;
95(3):
783 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kuramoto, T. Uesaka, A. Kimura, M. Kobayashi, H. Watanabe, and O. Katoh
ZK7, a Novel Zinc Finger Gene, Is Induced by Vascular Endothelial Growth Factor and Inhibits Apoptotic Death in Hematopoietic Cells
Cancer Res.,
January 1, 2000;
60(2):
425 - 430.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Salven, L. Teerenhovi, and H. Joensuu
A High Pretreatment Serum Basic Fibroblast Growth Factor Concentration Is an Independent Predictor of Poor Prognosis in Non-Hodgkin's Lymphoma
Blood,
November 15, 1999;
94(10):
3334 - 3339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Hefler, C. Tempfer, A. Obermair, K. Frischmuth, G. Sliutz, A. Reinthaller, S. Leodolter, and C. Kainz
Serum Concentrations of Vascular Endothelial Growth Factor in Vulvar Cancer
Clin. Cancer Res.,
October 1, 1999;
5(10):
2806 - 2809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Salven, A. Orpana, and H. Joensuu
Leukocytes and Platelets of Patients with Cancer Contain High Levels of Vascular Endothelial Growth Factor
Clin. Cancer Res.,
March 1, 1999;
5(3):
487 - 491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Wong, M. Alfert, D. H. Castrillon, Q. Shen, J. Holash, G. D. Yancopoulos, and L. Chin
Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome
PNAS,
June 19, 2001;
98(13):
7481 - 7486.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract